Background and aim Sophisticated technologies in rehabilitation, such as three-dimensional gait analysis, allow for measuring kinematic and kinetic variables while performing activities. The first peak external knee adduction moment (EKAM) is considered an important outcome in individuals with knee osteoarthritis (OA) and has been shown to be affected by changes in foot position in static trials. The present study aimed to explore the variables in static trials that may lead to changes in the value of the EKAM while walking. Methods Twelve individuals participated in the current study and were asked to perform three static trials as follows: 20° toe-out, straight (0°), and 20° toe-in. The participants were asked to walk five trials (their own shoes and paces). The first peak EKAM was the main study outcome and was compared between conditions. Linear regression was used to investigate which variables in the static trials significantly predicted the magnitude of change in the EKAM while walking. Results The first peak EKAM significantly decreased by 8.2% while walking when changing the foot position in static trials from 20° toe-in to 20° toe-out. The magnitude of change in the EKAM was significantly (p<0.01) predicted by the magnitude of change in the knee joint frontal plane angle, shank transverse plane angle, ankle joint frontal plane angle, and hip joint frontal plane angle during static trials between 20° toe-in and 20° toe-out. The model was able to predict 94% of the variation in the EKAM due to changes in foot position during static trials. Conclusion Modifications in foot position during static trials led to a change in the first peak EKAM while walking. Researchers should focus on controlling the knee joint frontal plane angle, shank transverse plane angle, ankle joint frontal plane angle, and hip joint frontal plane angle during static trials when conducting longitudinal or crossover studies. Controlling these variables is necessary to reduce the likelihood of the EKAM being affected by static trials and to ensure that the EKAM changes in dynamic trials are not masked or increased by static trials.